Navigation Links
ThromboGenics Announces Business Update and 2008 Full Year Results
Date:3/12/2009

ed that the most effective dose of microplasmin studied (125 ÿ¼g) was able to resolve the underlying disease in approximately 30% of patients within 1 week of treatment, removing the need for surgical intervention in these patients.

Microplasmin - Eye Disease: Phase III clinical program to evaluate non surgical treatment of patients with vitreomacular adhesion. In January 2009, ThromboGenics announced the start of the Phase III clinical program of microplasmin for the non-surgical treatment of back of the eye disease. The Phase III program comprises two clinical trials, taking place in the United States (TG-MV-006 trial) and combined Europe and US (TG-MV-007 trial). The initial indication for both of the Phase III microplasmin trials is the non-surgical treatment of focal vitreomacular adhesion. Both of these trials will use the 125ÿ¼g dose of microplasmin and include 320 patients each. Microplasmin for Vascular Disease - Encouraging Phase II results in acute ischemic stroke. In September, Professor Vincent Thijs, KULeuven, presented the results from this 40 patient study at the World Stroke Congress in Vienna, Austria. It remains ThromboGenics' intention that it will only move forward with the development of microplasmin for the treatment of stroke in conjunction with a partner.

TB-402 - Anti-coagulant: Begins Phase II trial in patients undergoing orthopaedic surgery. In February 2009, ThomboGenics announced that the first patient had been enrolled in the Phase II trial with their long-acting anticoagulant TB-402 for the prophylaxis of Deep Vein Thrombosis (DVT) following orthopaedic surgery. TB-402, which is given as a single injection post surgery, could overcome the major drawbacks such as bleeding and the need for extensive patient monitoring associated with current anti-coagulant therapy.

TB-403 - Anti-cancer: Positive results announced in Phase Ia study with TB-403 and start of Phase Ib st
'/>"/>

SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. ThromboGenics and BioInvent Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis
2. ThromboGenics N.V.: Business Update
3. ThromboGenics Announces Half Year Results 2008
4. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
5. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
6. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
7. ThromboGenics N.V. - Business Update
8. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
9. ThromboGenics Announces 2007 Full Year Results
10. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
11. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... (PRWEB) April 16, 2015 According ... overexertion involving an outside source was ranked first ... includes injuries related to lifting, pushing, pulling, holding, ... in direct costs. The David Round Company takes ... committed to working hard to develop and design ...
(Date:4/16/2015)... , April 16, 2015  RegeneRx Biopharmaceuticals, Inc. ... its U.S. joint venture with G-treeBNT (ReGenTree LLC) ... 3 clinical trial for the orphan disorder, neurotrophic ... for dry eye syndrome (DES) in the U.S.  ... drops, RGN-259/GBT201, this year.  Each of these eye ...
(Date:4/16/2015)... April 16, 2015  Scientists from Cleave Biosciences will ... the Horizon," at the American Association for Cancer Research ... on Sunday, April 19, 2015 from 3:15pm to ... of Biology, will present new in vivo and mechanism ... inhibitor of p97, a critical enzyme that controls various ...
(Date:4/16/2015)... 16, 2015 Fairleigh Dickinson University ... Gulfo to become the Executive Director of the ... announced the kick-off of the Initiative for Patient ... Dr. Gulfo, under the Rothman Institute of Innovation ... and in collaboration with FDU’s School of Pharmacy’s ...
Breaking Biology Technology:The David Round Company Helps Companies Meet OSHA Standards by Combining Safety, Ergonomics, and Productivity 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5Cleave Biosciences to Participate in Special Session "New Drugs on the Horizon" at AACR Annual Meeting 2015 2Cleave Biosciences to Participate in Special Session "New Drugs on the Horizon" at AACR Annual Meeting 2015 3Dr. Joseph V. Gulfo Named Executive Director of Fairleigh Dickinson University’s Rothman Institute to Spearhead New Initiative for Patient-Centered Innovation (iPCI) 2Dr. Joseph V. Gulfo Named Executive Director of Fairleigh Dickinson University’s Rothman Institute to Spearhead New Initiative for Patient-Centered Innovation (iPCI) 3
... Wis. - Commercial air service doesn't always ... viewed as more fundamental to enterprise than ever ... potential customers to dismiss the expenses of putting ... of Internet video and mixed-media communication tools. , ...
... a visit to the University of Wisconsin-Madison campus, former ... his name is under attack from critics who don't understand the ... at the annual Kastenmeier Lecture at the UW-Madison Law School ... Bayh-Dole Act , which gave universities the right to patent ...
... back, we took a look at the results of the National ... time, we saw that the Midwest had two states in the top ... top 20 states. I promised to circle back with you to review ... Midwest fared in this ranking. , ,The NIH falls under the ...
Cached Biology Technology:IP video goes where air travel cannot 2IP video goes where air travel cannot 3Landmark patent law under attack, Bayh says 2Landmark patent law under attack, Bayh says 3Midwest colleges strong contenders for NIH funds 2Midwest colleges strong contenders for NIH funds 3Midwest colleges strong contenders for NIH funds 4Midwest colleges strong contenders for NIH funds 5
(Date:3/20/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/vkzvcs/iris_biometrics ) ... Global Strategic Business Report" report to their offering. ... in US$ Thousands. The report provides separate comprehensive analytics for ... , Europe , Asia-Pacific ... Latin America . Annual estimates and ...
(Date:3/17/2015)... , March 17, 2015 ... company specializing in clinical study management systems, is ... in attendance at ARENA,s Outsourcing in Clinical Trials ... This event provides an excellent forum for MedNet ... flexible and affordable software-as-a-service (SaaS) eClinical technology platform. ...
(Date:3/16/2015)... , March 16, 2015 ... Systems GmbH will present groundbreaking innovations in biometric ... Hanover, Germany .      (Photo: ... latest biometric innovation is well at the forefront: ... generation e-gate made in Germany ...
Breaking Biology News(10 mins):Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 2DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 3
... Los Angeles, London, New Delhi, Singapore and Washington DC (July ... be advertised directly to the patient, and the results of ... the future adoption of pharmacogenetic/genomic testing, according to a position ... be published in the August 2009 issue of the ...
... many couples conceive healthy children and is generally considered ... PGD in mice suggests that this procedure may increase ... PGD is used alongside assisted reproduction technologies ... disease (e.g. Ashkenazi Jews who have a high incidence ...
... the July issue of Biomaterials , published by ... report on the first lab-grown motor nerves that are ... human body. The model system will drastically improve ... diabetic neuropathy and later, possibly multiple sclerosis (MS). In ...
Cached Biology News:Genetic tests advertised directly to the consumer 2Preimplantation genetic diagnosis may pose neurological risks 2Researchers design first model motor nerve system that's insulated and organized like the human body 2
... 60 rabbit tissue samples arrayed on Superfrost Plus ... and 1 hematoxylin and eosin (H&E) stained slide ... tissues from 4 rabbit organisms, for a total ... sample (or core) is 1.5 mm in diameter. ...
... [6331] to Salmonella typhimurium The genus Salmonella ... genus is composed of Gram-negative bacilli that are ... antigens; the "H" or flagellar antigen (phase 1 ... of the LPS moiety) and the "Vi" or ...
A univariate (peak height or area) quantitative multi-component analysis package....
... B1 series embodies all aspects of classical ... With powerful Achromatic Super Contrast (ASC) objectives ... chip, this microscope combines flexibility and professional ... popular B1 series, the DM-B1 steps into ...
Biology Products: